Evidence map›Paper›PMID 27800532›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2016

Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder.

Velina S Chavarro, Maureen A Mealy, Alexandra Simpson, Anna Lacheta, Florence Pache, Klemens Ruprecht, Stefan M Gold, Friedemann Paul, Alexander Ulrich Brandt, Michael Levy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Pain Symptoms in Optic Neuritis.Frontiers in pain research (Lausanne, Switzerland) · 2022
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Velina S ChavarroNeuroCure Clinical Research Center (V.S.C., A.L., F. Pache, F. Paul, A.U.B.), Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology (F. Pache, K.R., F. Paul), and Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin (S.M.G.), Charité-Universitätsmedizin Berlin, Germany; Department of Neurology (M.A.M., A.S., M.L.), Johns Hopkins University, Baltimore, MD; Experimental and Clinical Research Center (F. Paul), Max Delbrueck Center for Molecular Medicine, Berlin; and Institute of Neuroimmunology and Multiple Sclerosis (INIMS) (S.M.G.), Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Germany.
Maureen A MealyNeuroCure Clinical Research Center (V.S.C., A.L., F. Pache, F. Paul, A.U.B.), Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology (F. Pache, K.R., F. Paul), and Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin (S.M.G.), Charité-Universitätsmedizin Berlin, Germany; Department of Neurology (M.A.M., A.S., M.L.), Johns Hopkins University, Baltimore, MD; Experimental and Clinical Research Center (F. Paul), Max Delbrueck Center for Molecular Medicine, Berlin; and Institute of Neuroimmunology and Multiple Sclerosis (INIMS) (S.M.G.), Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Germany.
Alexandra SimpsonNeuroCure Clinical Research Center (V.S.C., A.L., F. Pache, F. Paul, A.U.B.), Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology (F. Pache, K.R., F. Paul), and Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin (S.M.G.), Charité-Universitätsmedizin Berlin, Germany; Department of Neurology (M.A.M., A.S., M.L.), Johns Hopkins University, Baltimore, MD; Experimental and Clinical Research Center (F. Paul), Max Delbrueck Center for Molecular Medicine, Berlin; and Institute of Neuroimmunology and Multiple Sclerosis (INIMS) (S.M.G.), Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Germany.
Anna LachetaNeuroCure Clinical Research Center (V.S.C., A.L., F. Pache, F. Paul, A.U.B.), Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology (F. Pache, K.R., F. Paul), and Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin (S.M.G.), Charité-Universitätsmedizin Berlin, Germany; Department of Neurology (M.A.M., A.S., M.L.), Johns Hopkins University, Baltimore, MD; Experimental and Clinical Research Center (F. Paul), Max Delbrueck Center for Molecular Medicine, Berlin; and Institute of Neuroimmunology and Multiple Sclerosis (INIMS) (S.M.G.), Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Germany.
Florence PacheNeuroCure Clinical Research Center (V.S.C., A.L., F. Pache, F. Paul, A.U.B.), Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology (F. Pache, K.R., F. Paul), and Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin (S.M.G.), Charité-Universitätsmedizin Berlin, Germany; Department of Neurology (M.A.M., A.S., M.L.), Johns Hopkins University, Baltimore, MD; Experimental and Clinical Research Center (F. Paul), Max Delbrueck Center for Molecular Medicine, Berlin; and Institute of Neuroimmunology and Multiple Sclerosis (INIMS) (S.M.G.), Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Germany.
Klemens RuprechtNeuroCure Clinical Research Center (V.S.C., A.L., F. Pache, F. Paul, A.U.B.), Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology (F. Pache, K.R., F. Paul), and Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin (S.M.G.), Charité-Universitätsmedizin Berlin, Germany; Department of Neurology (M.A.M., A.S., M.L.), Johns Hopkins University, Baltimore, MD; Experimental and Clinical Research Center (F. Paul), Max Delbrueck Center for Molecular Medicine, Berlin; and Institute of Neuroimmunology and Multiple Sclerosis (INIMS) (S.M.G.), Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Germany.
Stefan M GoldNeuroCure Clinical Research Center (V.S.C., A.L., F. Pache, F. Paul, A.U.B.), Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology (F. Pache, K.R., F. Paul), and Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin (S.M.G.), Charité-Universitätsmedizin Berlin, Germany; Department of Neurology (M.A.M., A.S., M.L.), Johns Hopkins University, Baltimore, MD; Experimental and Clinical Research Center (F. Paul), Max Delbrueck Center for Molecular Medicine, Berlin; and Institute of Neuroimmunology and Multiple Sclerosis (INIMS) (S.M.G.), Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Germany.
Friedemann PaulNeuroCure Clinical Research Center (V.S.C., A.L., F. Pache, F. Paul, A.U.B.), Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology (F. Pache, K.R., F. Paul), and Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin (S.M.G.), Charité-Universitätsmedizin Berlin, Germany; Department of Neurology (M.A.M., A.S., M.L.), Johns Hopkins University, Baltimore, MD; Experimental and Clinical Research Center (F. Paul), Max Delbrueck Center for Molecular Medicine, Berlin; and Institute of Neuroimmunology and Multiple Sclerosis (INIMS) (S.M.G.), Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Germany.
Alexander Ulrich BrandtNeuroCure Clinical Research Center (V.S.C., A.L., F. Pache, F. Paul, A.U.B.), Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology (F. Pache, K.R., F. Paul), and Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin (S.M.G.), Charité-Universitätsmedizin Berlin, Germany; Department of Neurology (M.A.M., A.S., M.L.), Johns Hopkins University, Baltimore, MD; Experimental and Clinical Research Center (F. Paul), Max Delbrueck Center for Molecular Medicine, Berlin; and Institute of Neuroimmunology and Multiple Sclerosis (INIMS) (S.M.G.), Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Germany.
Michael LevyNeuroCure Clinical Research Center (V.S.C., A.L., F. Pache, F. Paul, A.U.B.), Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology (F. Pache, K.R., F. Paul), and Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin (S.M.G.), Charité-Universitätsmedizin Berlin, Germany; Department of Neurology (M.A.M., A.S., M.L.), Johns Hopkins University, Baltimore, MD; Experimental and Clinical Research Center (F. Paul), Max Delbrueck Center for Molecular Medicine, Berlin; and Institute of Neuroimmunology and Multiple Sclerosis (INIMS) (S.M.G.), Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Germany.
Max Delbrück Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate depression frequency, severity, current treatment, and interactions with somatic symptoms among patients with neuromyelitis optica spectrum disorder (NMOSD).

methodsIn this dual-center observational study, we included 71 patients diagnosed with NMOSD according to the International Panel for NMO Diagnosis 2015 criteria. The Beck Depression Inventory (BDI) was classified into severe, moderate, or minimal/no depressive state category. We used the Fatigue Severity Scale to evaluate fatigue. Scores from the Brief Pain Inventory and the PainDETECT Questionnaire were normalized to estimate neuropathic pain. Psychotropic, pain, and immunosuppressant medications were tabulated by established classes.

resultsTwenty-eight percent of patients with NMOSD (n = 20) had BDI scores indicative of moderate or severe depression; 48% of patients (n = 34) endorsed significant levels of neuropathic pain. Severity of depression was moderately associated with neuropathic pain (

conclusionsModerate and severe depression in patients with NMOSD is associated with neuropathic pain and fatigue and is insufficiently treated. These results are consistent across 2 research centers and continents. Future research needs to address how depression can be effectively managed and treated in NMOSD.

Identifiers

PMID27800532
PMCPMC5079380
OpenAlexW2537017811

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.